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ABSTRACT 
 
Parrot bornaviruses are the etiological agents of proventricular dilatation disease 
(PDD), a fatal neurologic and gastrointestinal disease in birds. The virus is non-cytopathic, and 
the clinical presentation associated with the disease is due to inflammation and resulting 
injuries to the nerves. Mechanisms by which the virus evades and alters the immune system, 
thus producing disease, are not fully elucidated.  To investigate disease caused by parrot 
bornavirus infections, RNA-seq was used to identify differentially expressed genes in the 
brains of non-infected (control) and parrot bornavirus 2 (PaBV-2) infected mallard ducks. Our 
hypothesis was that ducks infected, in ovo, with PaBV-2 differentially express genes 
associated with the immune system as compared to non-infected ducks. Mallard eggs were 
inoculated in ovo with PaBV-2 at day 5 of incubation, with control eggs sham inoculated with 
diluent without virus. At 83 (+ 2) days post-hatch, ducks were euthanized; serum and 
cerebellum was collected and stored at -80°C until assayed. RNA from the cerebellar samples 
was sequenced, then RNA expression was quantified and compared between the groups. 
Differentially expressed genes with a significant difference (P < 0.01) between the infected 
and normal control ducks and a greater than or equal 4-fold change in expression were 
analyzed using Database for Annotation, Visualization, and Integrated Discovery and Kyoto 
Encyclopedia of Genes and Genome pathway database. From the samples, 18,146 genes were 
identified. Using the criteria of a P < 0.01 and a greater than or equal 4-fold change in 
expression, 41 genes had decreased expression and 9 genes had increased expression in the 
PaBV-2 infected ducks as compared to control ducks 
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NOMENCLATURE 
 
Anpl-DRA Anas platyrhynchos MHC class II alpha chain 
Anpl-U Anas platyrhynchos MHC class I alpha chain 
B2M Beta-2-microglobulin 
BDV Borna disease virus 
C Control duck (C1, C2, C3) 
CD74 Cluster of differentiation 74 
CS Clinical signs duck 
CTSS Cathepsin S 
DAVID Database for Annotation, Visualization, and Integrated Discovery 
DEG Differentially Expressed Genes 
EIF2AK2 Eukaryotic translation initiation factor 2 alpha kinase 2 
ELISA Enzyme-linked immunosorbent assay 
GO  Gene Ontology 
I Infected duck (I1, I2) 
IFN Interferon 
IRF Interferon regulatory factor 
Jak/STAT Janus kinases/signal transducer and activator of transcription 
KEGG Kyoto Encyclopedia of Genes and Genome 
MHC I Major histocompatibility complex class I 
MHC II Major histocompatibility complex class II 
MX Interferon-induced myxovirus resistance ynamin like GTPase 
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NGS Next Generation Sequencing 
PaBV Parrot Bornavirus 
PDD Proventricular Dilatation disease 
PKR Protein kinase RNA-activated (another name for EIF2AK2) 
PRR Pattern recognition receptor 
qRT-PCR Quantitative reverse transcription polymerase chain reaction 
RIG-I Retinoic acid-inducible gene I 
RNA-Seq RNA sequence 
RSAD2 Viperin 
RT-PCR Reverse transcription polymerase chain reaction 
STAT Signal transducer and activator of transcription gene 
SARS-CoV Severe acute respiratory syndrome coronavirus  
TANK Traf family member associated-activator NF-κB 
TAP Transporter associated with antigen processing 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TRIM25 Tripartite motif containing 25 gene 
WaBV Waterbird Bornavirus 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
1.1. General Virus information 
 
1.1.1 Parrot Bornavirus 
 
 Parrot Bornavirus (previously termed Avian bornavirus), in the Family 
Bornaviridae, are the etiological agents of proventricular dilatation disease (PDD), a fatal 
gastrointestinal and neurological condition of captive and wild birds. [1, 2] Bornaviridae 
are enveloped, non-segmented, negative sense RNA viruses that replicate inside the 
nucleus. Bornaviridae is comprised of eight species: Elapid 1 bornavirus found in reptiles,  
Mammalian 1 bornavirus and Mammalian 2 bornavirus  (also known as variegated 
squirrel bornavirus 1) found in mammals, and five species that infect birds:  Psittaciform 1 
bornavirus, Psittaciform 2 bornavirus, Passeriform 1 bornavirus, Passeriform 2 
bornavirus, and Waterbird 1 bornavirus. [3-6] The species of bornavirus associated with 
PDD are Psittaciform 1 bornavirus, which includes parrot bornavirus 1, 2, 3, 4, and 5 
(PaBV-1, -2, -3, -4, and -5), and Psittaciform 2 bornavirus, which includes parrot 
bornavirus 5 (PaBV-5). [7] 
 It should be noted that across different studies the nomenclature for avian bornavirus, 
first identified in 2008, is still evolving. As such, the nomenclature of avian bornaviruses is 
inconsistent when reviewing the history and literature. In an attempt for clarity in this 
manuscript, all literature focuses on parrot bornaviruses (PaBV), unless noted as otherwise.  
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1.1.2. History of Parrot Bornavirus 
 
Parrot bornavirus was determined to be the causative agent of PDD in 2008. Using 
isolates from PDD cases, investigations determined that PaBV was a new divergent form 
of bornavirus. [8, 9]  Both investigations used next generation technology and BLAST, and 
are the first PaBV experiments to use NGS technology.[8, 9] Parrot bornavirus was 
confirmed as the etiologic agent of PDD when Gray et al. (2010) followed Koch’s 
postulates and induced PDD in conures from PaBV infected brain samples of confirmed 
PDD case birds. [1]   
 
1.2. PaBV and the Immune system 
 
Cell cultures infected with PaBV have an ability to inhibit the production of type I 
interferons, essentially evading the activation of the innate immune system. [10] However, 
experimental infections of parrots trigger an inflammatory response. It was hypothesized that 
this inflammation may be due to the antibodies attacking the nervous system, similar to 
Guillain-Barre syndrome. This is still to be determined, as inoculation of PaBV brain 
gangliosides does not induce clinical PDD symptoms. [11] A second hypothesis is that 
infection of the nervous system by PaBV triggers an innate inflammatory response damaging 
the nerves, as PaBV has been consistently isolated from the damaged nerves in PDD cases. 
[12-17] 
 
 3 
 
1.2.1. PaBV Pathology 
 
Experimental routes of transmission, such as intramuscular, intravenous, and 
intracerebellar, are able to produce infection, histopathological lesions, and clinical PDD.[18-
21] Parrot bornavirus infections have also been vertically transmitted.[14, 22-25] Non-invasive 
routes that produce a robust infection are still to be determined. [26] Even if infection with 
PaBV is successful, an infected host may never develop PDD.[2, 18, 26-31] Parrot bornavirus 
antigens are shown to have broad distribution in infected birds. Antigens are consistently 
detected in the brain, spinal cord, heart, gastrointestinal system, adrenal gland, and kidneys by 
PCR and immunohistological tests. [27, 30, 32, 33] 
 
1.2.2. Techniques used for PaBV research 
 
Parrot Bornavirus can replicate in duck embryonic fibroblasts and quail cell 
cultures.[33-35] Reverse transcription-PCR (RT-PCR) is the most common detection protocol 
due to its ability to detect small amounts of viral RNA, however little information other than 
possible viral protein distribution can be extrapolated from these results. Reverse transcription-
PCR is routinely used in conjunction with immunohistochemistry and immunocytochemistry, 
both of which are less sensitive than RT-PCR but allow researchers to visualize viral load and 
viral distribution.[27] Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
allows for the quantification of viral amount. Parrot bornavirus antibodies can be successfully 
detected by western blot, immunoblotting, and enzyme-linked immunosorbent assay (ELISA). 
Western blot assays are particularly useful in determining if a bird has been exposed to PaBV. 
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[36] However, western blot protocols are lengthy. Immunoblotting and ELISA, for the 
detection of antibodies against PaBV, are not used as widely at RT-PCR or 
immunohistochemistry, which detect the PaBV antigen.[37, 38] For visualization of viral 
distribution, immunofluorescence and immunohistochemistry protocols are used, and have 
been used frequently in the study of PaBV. [28, 39] For each of these protocols, detection 
target should be taken into consideration, as it has been shown that birds can shed PaBV or 
have antibodies against it, but may not develop clinical PDD. [29, 36] References for protocols 
used are in table 1.  
 
 
 
Category Protocol Reference 
Molecular Techniques Tissue extraction of PaBV RNA 
RT-PCR 
Agarose gel electrophoresis 
50 
7, 50 
50 
Viral isolation techniques Growing PaBV in DEF 
PaBV isolation from tissues 
Serial dilution of PaBV 
Quantitate PaBV in a culture 
44, 46, 50 
50 
50 
48 
Serologic Techniques Western blot 
ELISA 
Immunohistochemistry 
10, 51 
10, 47, 48, 51 
10, 47, 48, 51 
 
 
 
Table 1. Protocol Reference Table 
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1.2.3. History of PaBV Research 
 
Investigators used high throughput sequencing to isolate the PaBV genome from 
confirmed cases of PDD when first confirming if PaBV was the etiologic agent of PDD. 
Reverse transcription-PCR was used to confirm that the viral genome isolated from confirmed 
cases of clinical PDD matched viral sequences in experimentally infected PDD cases. [8, 9] 
Kistler et al. (2008) were the first to identify a novel bornavirus as a causative agent of 
PDD. [8] Using a high throughput assay, ABV (subsequently named PaBV) was found in 
naturally occurring cases of clinical PDD but not found in non-clinical birds. [8] At roughly 
the same time, Honkavuori et al. (2008), found by pyrosequencing of cDNA from the tissues 
of 2 macaws and one Amazon parrot that had clinical PDD, two novel strains of bornavirus in 
the birds’ brain, proventriculus, and adrenal gland. [9] Gray et al. (2010) used Koch’s 
postulates to connect these novel bornaviruses, PaBV, as the etiological agent of PDD. [1]  
Experimental inoculation with PaBV is a useful method to study the pathology of 
PDD. However, the use of large parrots, such as macaws, Amazons and African Greys that are 
naturally susceptible to naturally occurring PDD is not practical due to many reasons: expense, 
emotional value, and endangered statue of some large parrots. Gancz et al. (2009) induced 
histopathological lesions and clinical manifestation of PDD in cockatiels (Nymphicus 
hollandicus) when brain homogenates containing avian bornavirus 4 were inoculated by 
multiple routes (intramuscular, intraocular, intranasal, and oral). [40] Subsequently, cockatiels 
have become the main species used for PaBV studies, including those studying natural 
infection routes, pathogenesis, and analysis of different PaBV strains. [19, 26, 41, 42] Other 
bird species, usually collections of species at aviaries, used successfully to investigate parrot 
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bornavirus include: conures, lovebirds, macaws, African greys, and cockatoos. [37, 43]   Monk 
parakeets and budgerigars have been resistant to experimental infection by PaBV. [1]  
Recently, PaBV has been isolated from waterfowl, and some passerines, naturally 
occurring in the wild. [13, 21, 23, 29, 34, 44, 45] However, the use of these birds as a research 
model is limited, as most of the studies have been from hunter-collected samples. [13, 17, 29, 
34, 44] Parrot bornavirus 2 and parrot bornavirus 4 are the species used most in research as 
they are the species most often isolated from naturally occurring clinical PDD cases, most 
prevalent species occurring in North America and Europe, and have consistently produced 
histopathological lesions and clinical PDD in experimentally infected birds. [14, 15, 41, 43, 
46] 
 
1.3. Proventricular Dilatation Disease 
 
In parrots, PDD is classified as a disease that affects the neurological and 
gastrointestinal system. Neurologic symptoms include general weakness, ataxia, declining 
proprioception, seizures, and blindness. Histopathology findings of lymphoplasmacytic 
inflammations throughout the nervous system, with lesions involving the ganglia of the enteric 
system, constitutes a definitive diagnoses of PDD. [2, 18, 42] Gastrointestinal symptoms 
include weight loss, regurgitation, passage of undigested food, and delayed crop emptying. As 
the name of the disease suggests, affected birds have a dilated proventriculus with thinning 
walls due to impaction theorized to be caused by damage to the enteric nervous system. [18, 
42] These symptoms occur in acute PDD. Parrot bornavirus has been shown to be an 
etiological agent of PDD, but birds can be infected with PaBV without clinical signs of PDD, 
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otherwise known as carriers. [1, 2, 42, 47]  As mentioned previously, there is broad tissue 
distribution of PaBV antigens in infected birds with the production of PaBV antibodies, but a 
definitive diagnosis of PDD is only made when lymphocytic ganglioneuritis is found in the 
enteric nervous system, thus PDD confirmation is a post-mortem diagnosis. [17, 33, 36, 48] 
Waterfowl throughout northern America are infected with waterbird bornavirus 
(WaBV), and WaBV does not seem to cause clinical PDD in parrots. [13, 17, 29] It is 
speculated that WaBV may cause a neurological disease similar to PDD, however, most of the 
studies of WaBV use brains that are from birds that were found dead or hunter collected, so 
there is no observation of symptoms. [23, 29, 34, 44, 49, 50] Lesions typical of PDD cases are 
seen in the brains of waterfowl, however as mentioned earlier, to confirmation is based upon 
lymphocytic infiltration of the enteric ganglia and these tissues are not routinely available. [13, 
18, 42] It remains to be seen if waterfowl infected with PaBV would show PDD like 
symptoms, as the similar lesions occur from both PaBV and WaBV. 
 
1.4. Studies into PaBV Pathology 
 
The pathology of how PaBV is able to cause PDD is not linear. There are accounts of 
birds being infected with PaBV, determined through PCR or western blot, but they don’t 
develop PDD. [27, 29, 36, 48] Additionally, infection detection is not always consistent, with 
cloacal swabs being the most inconsistent and brain samples being consistently positive across 
multiple PaBV studies. [27, 31, 51] Furthermore, not all bird species develop clinical PDD 
following infection. [8, 9, 40, 52] While some birds remain fully asymptomatic, other birds 
that were consistently negative for PaBV may develop PDD and die quickly after contracting 
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PaBV. [27, 29, 48] As for treating PDD, at this time there is no proven efficacious treatment 
for infection or for reducing viral shedding. Most treatments reduce the severity of PDD 
symptoms. [2, 18] Most symptomatic treatments use non-steroidal anti-inflammation drugs, as 
PDD symptoms are theorized to be a result of inflammation to PaBV replicating in the 
neurons. NSAIDS effectiveness is variable, as PDD can increase in severity with the use of 
Meloxicam compared to the relative success of Celecoxib. [2, 53] There is some evidence that 
conjugation of ABV proteins with New Castle disease and a modified vaccinia virus can resist 
PDD development, however, this is still in development. [54] Overall, there is a dearth of 
information on the mechanisms by which PaBV produces disease. Therefore, incorporating 
next generation sequencing technology would add another aspect that could elucidate the 
pathology of PaBV, in particular the host-virus interactions. 
 
1.5. Gene Expression Changes: Viral Infection 
 
To survive in a host some viruses have the ability to hijack a cell’s regulation of gene 
expression. It is unknown if PaBV uses this strategy to cause disease, but this may be 
elucidated by using next generation sequencing (NGS) technology. Next generation 
sequencing technology has been used in PaBV studies to determine novel species, but the 
full capacity of this technology has not been explored. [8, 9, 40, 55] For instance, NGS 
technology has been used to determine new species of PaBV that infects waterfowl and 
passerines. [8, 9, 34, 56] 
Using NGS technology to study bird viruses is not unprecedented and has been 
successful in revealing viral-host interactions. Most of these studies are of chickens and those 
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diseases that harm chicken meat and egg production. Response to stressors such as heat, 
growth rate, and even exposure to ammonia in chickens have shown to cause changes to gene 
regulation. [57-59] Viral and bacterial infection of chickens, including influenza A and avian 
pathogenic E. coli, have been shown to cause changes to gene regulation that induce a disease 
in chickens. [60-63] For instance, avian influenza virus studies suggested that infection was 
correlated to changes in cell signaling pathways, viral response pathways, and cellular protein 
production. [64-67] Additionally, differentially expressed genes caused by coronavirus 
infection of apparently healthy chickens supported evidence that the virus is able to escape 
recognition by the immune system. [61, 68] 
These viral studies are not limited to chickens. Ducks are the alternative bird of choice 
in chicken production studies as most of their genome is available to use for analysis. [69-72] 
There are multiple studies on differentially expressed genes occurring when ducks are infected 
with viruses. [55, 73-77] For instance, ducks are used in influenza A studies; ducks are a 
reservoir species whereas chickens develop the disease. [78] There are multiple precedents of 
sequencing technology being used to investigate host-virus interactions in respect to gene 
expression. Parrot bornavirus is not one of those precedents, but Borna disease virus (BDV) 
has been analyzed with next generation technology. Studies in rats infected with BDV have 
differentially expressed genes associated with the kynurenine pathway causing 
neurodegeneration.[79] Essentially, differential gene expression is able to suggest effects that a 
virus may have on cellular gene expression, thus elucidating mechanisms that allow for the 
survival and replication of the virus within the host. 
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1.6. History of RNA-Seq 
 
Most experiments before next generation technology used microarrays which gave a 
snapshot of gene expression at one point in time. Unlike NGS, microarrays allowed 
researchers to visualize gene regulation. However, microarrays are limited to amount of RNA 
it can hybridize as it has a linear dynamic range.[80, 81] Next generation technology has a 
larger dynamic range, can analyze large amounts of data, and is relatively quick and cheap as 
compared to microarrays. Additionally, NGS is not exclusive, any researcher with enough 
storage space and an internet connection can have access to multiple free bioinformatics tools 
available online. [80-83] Finally, as mentioned earlier, NGS technology has a better dynamic 
range than microarrays. Even short sequence fragments are able to be detected in the genome, 
unlike microarray. Additionally, using RNA-Seq, an NGS tool, allows researchers to analyze 
multiple different cellular operations like meiotic differentiation, the occurrence of rapid 
cellular proliferation, responses to environmental stressors and even the discovery of mutant 
RNA. [80, 81] 
1.6.1. Next Generation Sequencing Technology Limitations 
 
There are some limitations to NGS abilities. For instance, large data outputs of genetic 
information will need a large storage capacity to perform statistical analysis and normalization. 
Without the analysis, the data is not useable. Parsing out significant data points from a large 
data output may require additional technical help from bioinformaticists. Technical knowledge 
of types of sequencing analysis, most available software, and overall computer knowledge is 
necessary to fully extrapolate all significant data from the output of NGS. [84] 
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1.6.2. Methodology of Next Generation Sequencing 
 
Most NGS projects outsource sequencing, and get back the output of genetic data. 
Previously, all projects that used next generation technology were exclusive to organizations 
that had the technology and the technical knowledge to analyze genetic data. Now researchers 
can have access to online software capable of exacting statistical analysis on genetic 
information without having advanced knowledge of coding languages or statistics. [81-83, 85] 
One popular method of sequencing samples is with technology produced by Illumina. 
(Illumina HiSeq 4000, Illumina, Inc., San Diego, CA) Companies such as this have helped 
drive down the cost of sequencing and helped streamline the sequencing process. [82, 83, 86, 
87] 
While sequencing can be outsourced, preparation of the samples is not. For RNA-Seq, 
RNA is extracted, isolated, and purified. The purity of the RNA sample is key to avoiding 
errors in sequencing. To keep purity and avoid RNA degradation, it is recommended that 
samples are frozen once obtained either by keeping it in a freezer or immediately freezing a 
sample with liquid nitrogen. [82]  After sequencing and qualitative reads are performed and 
the researcher receives the data output, the data is ready for analysis. There are many types of 
software available for analysis, and one with a consumer friendly interface is CLC Genomics 
Workbench. (CLC Bio Genomic Workbench, Qiagen Inc.) CLC Genomics Workbench is a 
collection of analysis software necessary for different sequencing tasks. [88] For instance, for 
RNA-Seq, CLC Genomics Workbench has incorporated the EdgeR Bioconductor package 
which statistically analyzes and normalizes expression data. [89, 90] Additionally, this 
package introduces the least amount of bias during normalization. [89, 91-93] Once 
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normalized, the genetic data can be analyzed by online tools like the Database for Annotation, 
Visualization, and Integrated Discovery (DAVID), and the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) database to discover gene information including biological functions and 
pathways.[94-98]  
 
1.6.3. RNA-Seq and Infectious Disease 
 
The NGS technology, RNA-Seq, is effective at creating expression profiles to 
determine differentially expressed genes. This type of analysis, called differential gene 
expression (DEG) analysis, is a suitable approach to identify changes in gene transcription 
when viruses alter cellular regulation, and may indicate how PaBV is able to cause pathology. 
This type of analysis is also regularly used in the study of infectious avian diseases instead of 
microarrays. [61, 62, 66, 67] RNA-Seq of PaBV has been used to determine new strains, but 
not for DEG analysis. Other types of viruses have previously used DEG to infer possible host-
virus interactions. Nervous necrosis virus upregulates genes related to the innate immune 
system in brain cells, and it is theorized that genes like lectins and chemokine ligand 2 (CCL-
2) were regulators of regulation. [99] Muscovy ducks infected with reovirus had upregulation 
of transcription factor regulators, and signaling pathway receptors including the retinoic acid-
inducible gene I (RIG-I)-like and toll-like receptors. [73, 100]  In chickens, DEG analysis 
indicated a correlation between immune recognition evasion by the avian influenza virus and 
gene expression of infected cells. [67] In respect to ducks and infectious viruses, the 
transcriptome of different ducks has been analyzed for infections of influenza A virus, avian 
paramyxovirus, and avian coronavirus to understand the diversity of such viruses in mallard 
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duck populations. [74, 101] Using RNA-Seq to perform DEG on PaBV infected animals may 
provide insight into the pathology of a PaBV infection and PDD. 
 
1.7. Precedents in PaBV Pathology 
 
There is no dearth of pathological theories of a PaBV infection. One theory is that 
PaBV is autoimmune, and similar to Gulliarn-Barre syndrome in presentation. However, this 
may not be the case as autoantibodies against gangliosides do not cause symptoms or lesions 
similar a typical PDD case. [1, 2, 11, 18] However, there is evidence that PaBV has a transient 
autoimmune response to myelin and brain gangliosides when infected with PaBV as detected 
by western blot. [18] Cellular pathology of the virus has been visualized using 
immunofluorescence of PaBV infected cells which shows the virus occupying the nucleus of 
duck embryonic fibroblasts. [31, 39] This method is also used to detect PaBV infection in 
other animal cells, as indicated by a viral loaded nucleus. [12] In developing PaBV detection 
methods, the pathology of PaBV is further elucidated. During the development of PCR for 
PaBV, it was found that viral proteins could be broadly distributed in tissues and even in 
feather shafts, but not in the blood. [102] Additionally, PCR testing of cloacal swabs found 
that viral shedding was an inconsistent detection method for confirming viral infection, as the 
virus can be infrequently and inconsistently shed. [29, 31, 51] This raises the question in the 
difference between clinical PDD cases and asymptomatic cases of PaBV infection. The 
development western blot was able to elucidate immune response to PaBV. Western blot has 
shown that birds do develop antibodies against the nucleoprotein (N-protein) and 
phosphoprotein (P-protein) of PaBV, and that birds can be seropositive due to exposure to the 
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virus. [36] Unlike PCR, western blot is able to detect proteins in blood. [36] However, western 
blot is not frequently used as a detection method due to time required to perform the protocol. 
Overall, the development of PaBV detection methods have been significant in elucidating 
PaBV pathology but do not give insight into host-virus interaction on a genetic level as RNA-
Seq may be able to do. 
 
1.8. RNA-Seq and PaBV 
 
To the best of our knowledge, there is not a precedent of DEG being performed on PaBV 
infected animals to elucidate virus-host interaction effects on gene expression. Proventricular 
dilatation disease (PDD) can present with neurological symptoms, and PaBV does infect 
neurological cells, but it is only theorized how PaBV causes inflammation to induce such 
neurological symptoms. [1, 18] The virus is non-cytopathic, therefore damage is not due to 
direct viral destruction of cells, and additionally, there is no evidence of an autoimmune 
response to infected neurological cells causing the symptomatic neurological signs. [17, 18] 
The theory of inflammation is based upon previously mentioned detection methods, which do 
not give insight into virus-host cell interactions unlike RNA-Seq and subsequent DEG 
analysis. RNA-Seq and DEG analysis quantify transcripts and create gene expression profiles 
of sampled tissues. If these tissues sampled were from the cerebellum of a clinical PDD case 
bird, then determination of differentially expressed genes would be insightful, as the 
cerebellum has been shown to have a high load of PaBV in PDD cases. [27, 52] Essentially, 
RNA-Seq paired with DEG analysis is able to give insight into PaBV’s pathology that 
previous viral detection methods are not capable of doing. 
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1.8.1. Reference Genome: PaBV and Ducks 
 
Few avian species are vulnerable to a PaBV infection and have a quality annotated 
genome necessary for RNA-Seq. This is because few psittacine genomes have been sequenced, 
and fewer have been annotated for genes. However, the mallard duck does have a quality 
annotated genome. [69, 70, 74, 103-118] Additionally, mallard ducks have been shown to 
become infected with WaBV, a species of virus similar to PaBV. [23, 27, 29, 34] Therefore, 
for a preliminary test to see if there is any significance to using RNA sequencing on PaBV 
infected birds, the mallard duck is the most reasonable choice 
 
1.9. Hypothesis and Objectives 
 
Our hypothesis is that ducks infected, in ovo, with PaBV-2 have differentially 
expressed genes associated with the immune system as compared to non-infected ducks.  
Objectives to test our hypothesis will be: 
1.  to determine baseline gene expression, using RNA-Seq technology, in the 
cerebellum   of uninfected control ducks; 
2. to identify genes expressed, using RNA-Seq technology, in ducks infected with 
PaBV-2; and, 
3. to analyze differential gene expression to identify dysregulated genes in PaBV-2 
infected ducks as compared to uninfected ducks. 
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CHAPTER II 
 MATERIALS AND METHODS 
 
2.1. Objective 1:  Create a baseline gene expression on cerebellum of uninfected ducks 
 
Mallard (Anas platyrhynchos) eggs were obtained from a commercial farm (Metzer 
Farms, Gonzales, CA). Eggs were incubated at 37.5° C at 55-60% relative humidity.  At 5 
days incubation, the eggs were injected with the 0.1 ml inoculation solution without PaBV-2. 
The inoculation solution was made from duck embryo fibroblast cells grown in media that 
were freeze-thawed 3 times, centrifuged, and the diluent collected as the inoculation solution. 
On day 83 (+ 2) post-hatching, ducks (n=3), C1, C2, and C3, were euthanized and necropsied. 
Cerebellum and hindbrain samples were collected and stored in 1.5mL microcentrifuge tube at 
-80°C until assayed. To determine infections status, cerebellum and hindbrain were assayed by 
RT-PCR using an M-protein sequence primer. Serum taken during necropsy was assayed by 
western blot for the presence of antibodies to viral N-protein, the immunodominant epitope in 
avian bornaviruses.  
Samples of cerebellum were processed for RNA isolation by utilizing a commercial 
RNA isolation product (NucleoSpin® RNA Plus, Macheney-Nagel Inc., Bethlehem, PA). 
RNA isolation followed product protocol (Appendix A. Fig A1) with minor modifications 
noted here. Briefly, 550uL of LBP Buffer was added to 30uL of sample and fully 
homogenized by pellet mixer (VWR® Disposable Pellet Mixers and Cordless Motor, VWR 
International, Radnor, PA). Samples were incubated at room temperature for 10 minutes, 
examined for complete homogenization, and if not fully homogenized, 100 uL of additional 
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LBP buffer was added and the sample was homogenized again. Full homogenization was 
necessary as tissue can disrupt proper gDNA removal and lead to contamination of the final 
RNA isolate. The sample was then loaded on a NucleoSpin® gDNA Removal Column 
(Macheney-Nagel Inc.), centrifuged for 30 second at 11000x g, and the eluent collected. The 
eluent was then combined with 100uL of RNA Binding Solution and run through a 
NucleoSpin® RNA Plus Column and centrifuged for 15 seconds at 11000x g. The column was 
washed with Buffer WB1 solution (Macheney-Nagel Inc.) and then two additional washes 
with the Buffer WB2 (Macheney-Nagel Inc.). A final wash with the Buffer WB2 was done and 
the column was centrifuged twice for 2 minutes at 11000x g. The RNA was eluted from the 
column by adding 50uL of RNAse free H2O (Macheney-Nagel Inc.), centrifuging for 1 minute 
at 11000x g, and collecting the eluent. The eluent, containing the isolated RNA, was stored at -
80°C. For each sample, the process was done in triplicate to obtain biological replicates for 
RNA-Seq to account for biological variation across samples.  
Eluted RNA samples were assayed for purity and concentration using a commercial 
product (NanoDrop 2000, ThermoFisher Scientific, Houston, TX ) using the standard product 
protocol; purity needed to be 260/280 and 260/230 absorbance ratios above 1.8 and 
concentration above 100 ng/uL. The device was blanked using the same RNAse free H2O used 
to elute samples during RNA isolation. . 
 Samples were then diluted, with RNAse free H2O, to a concentration of 45 ng/uL, a 
criteria for RNA-Seq. The samples were submitted to Texas A&M AgriLife Genomics and 
Bioinformatics Services (TxGen) for RNA-Seq by Illumina TruSeq RNA library preparation 
protocol using the Hiseq 4000 platform. 
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 2.2. Objective 2:  Identify genes expressed in cerebellum of ducks infected with PaBV-2 
 
Eggs and the environment for egg incubation is described in Objective 1. At 5 days 
incubation, the eggs were injected in ovo with 0.1mL of PaBV-2 inoculation solution 
containing 8x10-6 focus forming units (FFU). The inoculation solution was made from duck 
embryo fibroblast cells infected with PaBV-2, allowed to grow for 5 days, then freeze-thawed 
3 times, centrifuged, and the diluent collected as the virus inoculation solution. Infected ducks, 
(n=3) I1, I2, and I3, were euthanized on day 83 (+ 2) post-hatch. Samples were collected, 
processed, and analyzed exactly as samples in Objective 1. If any clinical PDD-like symptoms 
were observed in a duck, additional tissues were taken for RT-PCR and histopathology 
(Appendix A. Table A1). 
 
 2.3. Objective 3: Use bioinformatics software to analyze the differential gene expression 
found between uninfected and PaBV-2 infected ducks 
 
Raw data from the RNA-Seq run was compressed into a .tar file by Texas A&M 
AgriLife Genomics and Bioinformatics Services (TxGen). These files were then unpacked 
using 7-zip software and imported to the bioinformatics software, CLC Bio genomic 
workbench (Qiagen Inc.)(Appendix A. Fig.A3). [119] The raw RNA sequences were then 
mapped to a mallard duck reference genome release 1.0. The reference genome sequences 
were obtained from the ftp site developed by the National Center for Biotechnology 
Information (NCBI GenBank, National Center for Biotechnology Information, Bathesda, MD). 
[120] Mallard duck genome is still under construction, therefore, the detailed information such 
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as chromosome level sequences are not available yet. The current consensus genome consists 
of long sequences generated by assembly process, as well as annotation information to locate 
the recognized genes on these sequences. In order to generate the gene expression profiles for 
samples, the RNA-Seq output sequences, called reads, were mapped to the mallard duck 
reference release 1.0, using the CLC Bio genomics workbench “RNA-Seq Analysis” tool 
(Appendix A. Fig. A4). [119] The CLC Bio genomic workbench provides a plug in, 
“Annotating with GFF file”, for incorporating the annotation information into the duck 
genome (Appendix A. Fig.A5). [119] Alignment of RNA-Seq reads to the mallard duck 
annotated reference genome, which was elaborated above, resulted in average 50% of genes 
mappings (Appendix A. Table A2). As a test, we used chicken reference genome for alignment 
and the mapping percentages were considerably lower. Comparatively, these results are 
valuable in studying the genes causing the disease as there is no reference genome for parrots 
that are susceptible to a PaBV infection. For each RNA-Seq mapping run, we used the 
following settings: 
 
Mapping Type: Gene Regions; Mismatch cost: 2; Insertion Cost: 3; Length fraction: 0.85; 
Similarity fraction: 0.85; Global Alignment: yes; Strand specific: both; Maximum # of hits: 1; 
Count paired reads as 2: no; Expression Value: RPKM; Calculate RPKM for gene without 
transcript: no; Create report: yes 
  
Normal reads checks were performed after mapping to check for consistency in 
mapping results (Appendix A. Table A3). Mapping reads to the genome generates expression 
values for each gene that was provided in the annotation file. Upon completion of alignments, 
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we used the “Setting Up an Experiment” tool in CLC Bio genomics workbench to organize the 
mapping results into comparable groups (Appendix A. Fig. A6).[119] The comparisons 
between infected (I1, I2, CS) and control groups (C1, C2, C3) with 3 biological replicates were 
set up using the following parameters: 
 
Expression Value level: As set on samples; Expression value column: As set on samples; 
Experiment Type: Two group comparison; Number of samples in experiment: Varies 
  
To normalize the data from these experiments, statistical analysis was performed using 
the CLC Bio software called, “Empirical Analysis of DGE” (Appendix A. Fig. A7). [119] The 
DGE stands for Digital Gene Expression, and it is used to account for difference between 
sequencing outputs of samples, such as different output amount. This criteria is set for each 
DGE analysis: 
  
Total Count filter cutoff: 5.0; Estimate tagwise dispersions: Yes; Comparisons: All Pairs 
Bonferroni corrected: Yes; FDR corrected: Yes 
  
In the next step, “Empirical analysis of DGE” tool was employed to compare the gene 
expression among the group. The previous experiments were used in this analysis. The 
“Empirical analysis of DGE” tool implements the two groups tested for significance based on 
the edgeR package of R. [119] 
To select the most significant genes, the “Empirical analysis of DGE” performs 
multiple comparisons. There are methods to correct for multiple testing and CLC uses 
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Bonferroni and False Discovery Rate (FDR). [119] In this study we chose the expressions 
based on the Bonferroni p-value, as it is more conservative than the FDR p-value. Tables of 
genes that are both significant and either upregulated or downregulated were further analyzed 
to identify gene functions based on previously published articles, NCBI’s e!Ensembl (National 
Center for Biotechnology Information, Bethesda, MD), and GenBank (National Center for 
Biotechnology Information) as the gene catalogues. [121, 122] To analyze biological function 
and pathways of these differentially expressed genes, the gene I.D.’s from Genbank (National 
Center for Biotechnology Information) were uploaded on to the Database for Annotation, 
Visualization, and Integrated Discovery (DAVID) and the Kyoto Encyclopedia of Genes and 
Genome (KEGG) pathway database. [94-98] Finally, the most significant genes were analyzed 
to determine if significance is constant for each infected duck. 
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Table 2. PCR and Western Blot Results of Sampled Ducks. After necropsy, brain tissue and serum were taken for 
testing. Control ducks are labeled as C1, C2, and C3. Infected ducks are labeled as I1 and I2. The clinical signs 
duck is labeled as CS. (Appendix B. Table B2. CS duck detailed PCR results) 
CHAPTER III  
RESULTS 
 
3.1. Infection confirmation of ducks 
 
 For control ducks, no viral genetic material was detected in the cerebellum or 
hindbrain; PCR results were negative. No antibodies against the PaBV-2 viral N-protein was 
detected by western blot (Table 2).  
One duck became severely ataxic and was euthanized on day 65 (supplementary materials 
contains video of ataxic signs). This duck is subsequently referred to as clinical signs (CS) 
duck. Additional tissues taken from and additional observation of the CS duck can be found in 
appendix B. 
 All infected ducks were positive for PaBV-2 by RT-PCR (Figure 1). Only 2 infected 
ducks were positive for antibodies against the viral N-protein from western blot, I1 and CS 
(Table 2).  
 
 
 
  
Test Sample 
Control Infected 
C1 C2 C3 I1 I2 CS 
Western Blot Serum - - - + - + 
Cerebellum - - - + + + 
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PCR 
 
Hindbrain - - - + + + 
3.2. Host expression profile after PaBV-2 infection 
 
The analysis identified 18,146 genes. Comparing control to infected ducks, 231 genes were 
significantly (P < 0.01) differentially expressed. Of these 231 significantly differentially 
expressed genes, 49 genes had greater than or equal to a 4-fold change in expression; 41 had at 
least a 4-fold decrease in expression and 8 had at least a 4-fold increase in expression (Table 3).  
Eleven genes had a fold change > |100|; 9 were down regulated and included 4 C-C motif 
chemokine genes (LOC101800938, LOC101800921, LOC101791569, LOC101791385), 
interferon-induced myxovirus resistance dynamin like GTPase (MX), viperin (RSAD2), 
placenta specific 8 (PLAC8), interferon-induced protein with tetratricopeptide repeats 
(LOC101797569), and interferon-induced alpha-inducible protein (LOC101794704), while the 
2 upregulated genes included transcription factor BTF3 (BTF3) and 60s ribosomal protein L37 
(LOC106020377).  
Since neurological clinical signs in a PaBV-2 infected duck is unprecedented, a second 
expression profile was created to compare the differential expression in the clinical sign duck 
to the control ducks (C1, C2, C3). Out of the identified 18,142 genes, 185 genes were 
significantly (P < 0.01) differentially expressed. Of these 185 genes, 71 had a greater than or 
equal to 4-fold change; 54 had at least a 4-fold decrease in expression and 17 had at least a 4-
fold increase in expression (Table 4). Eight genes had a fold change > |100|; 6 were 
downregulated and included C-C motif chemokine 4-like (LOC101800938), interferon-induced 
myxovirus resistance dynamin like GTPase (MX), viperin (RSAD2), interferon-induced protein 
with tetratricopeptide repeats (LOC101797569), interferon alpha-inducible protein 
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(LOC101794704), and prolactin-releasing peptide receptor (LOC101801882). Upregulated 
genes included 60s ribosomal protein (LOC106020377), and transcription factor BTF3 
(BTF3). The full table of genes with a P <0.01 is depicted in Appendix B. 
 
 
 
 
Figure 1.  Image of PCR Results. From left to right, after the PCR ladder are control duck results, PCR controls, 
and cerebellum results for I1 and I2. After the second ladder is the cerebellum result for the clinical sign duck, 
followed by the second set of PCR controls.  
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Anapl_12933 101794704 LOC101794704 interferon alpha-inducible protein 27-like protein 2B -366 1.91E-116
Anapl_18401 101797569 LOC101797569 interferon-induced protein with tetratricopeptide repeats 5 -285 0.00E+00
Anapl_04893 101800938 LOC101800938 C-C motif chemokine 4-like -250 1.85E-59
Anapl_18425 101800921 LOC101800921 C-C motif chemokine 4 -154 4.18E-39
Anapl_01687 101791569 LOC101791569 C-C motif chemokine 4-like -152 2.88E-37
Anapl_13350 101793492 MX interferon-induced GTP-binding protein Mx-like -139 8.24E-57
Anapl_14386 101791352 RSAD2  viperin, radical S-adenosyl methionine domain containing 2 -120 1.91E-52
Anapl_01685 101791385 LOC101791385 C-C motif chemokine 5-like -115 5.56E-37
Anapl_05957 101791974 PLAC8 placenta specific 8 -114 1.80E-92
Anapl_08494 101795904 IRF7 interferon regulatory factor 7 -99 6.97E-87
Anapl_14385 101790338 CMPK2 cytidine/uridine monophosphate kinase 2 -58 9.49E-44
Anapl_02580 101793511  SAMD9L sterile alpha motif domain-containing protein 9-like -48 1.69E-48
Anapl_13382 101798516 EIF2AK2 interferon induced eukaryotic translation initiation factor 2 alpha kinase 2-42 6.18E-39
Anapl_03170 101800860  SAMD9L sterile alpha motif domain-containing protein 9-like -38 8.65E-73
Anapl_19105 101790497 Anpl-U  class I histocompatibility antigen, F10 alpha chain    -31 3.10E-48
Anapl_16041 101797680 TAP1 transporter 1 -29 1.09E-42
Anapl_06165 110351393 SRGN serglycin -29 2.01E-28
Anapl_18444 101805361 PLVAP plasmalemma vesicle associated protein -24 2.48E-88
Anapl_09160 101796142 LOC101796142 interferon regulatory factor 4-like -21 4.74E-35
Anapl_03154 101791574 TRIM25 tripartite motif containing 25 -20 1.21E-74
Anapl_03165 106014788 RNF135 ring finger protein 135 -18 4.41E-31
Anapl_17300 101799633 IRF1 interferon regulatory factor 1 -12 6.73E-73
Anapl_16039 101797091 TAP2 transporter 2 -11 2.04E-46
Anapl_01734 101799108 B2M beta-2-microglobulin -11 5.22E-74
Anapl_00935 101798744  PARP14 poly [ADP-ribose] polymerase 14 -11 2.81E-29
Anapl_09935 101790771 TLR3 toll like receptor 3 -10 2.19E-18
Anapl_04378 101803758 C1QA complement C1q A chain -9 6.41E-36
Anapl_12048 101803806 USP18 ubiquitin specific peptidase 18 -9 2.05E-49
Anapl_10110 101789908 LOC101789908 poly [ADP-ribose] polymerase 14 -8 1.93E-65
Anapl_04377 101803105 C1QB complement C1q B chain -7 3.25E-33
Anapl_02056 101801059 MOV10 Mov10 RISC complex RNA helicase -7 1.50E-18
Anapl_17425 101789604 LOC101789604 class II histocompatibility antigen, B-L beta chain -7 1.78E-25
Anapl_10146 101797758 NMI N-myc and STAT interactor -7 1.34E-47
Anapl_09516 101794564 CTSS cathepsin S -6 1.93E-21
Anapl_10109 101789724 PARP9 poly(ADP-ribose) polymerase family member 9 -6 5.28E-24
Anapl_07454 101796809 LOC101796809 probable E3 ubiquitin-protein ligase HERC3 -6 8.98E-31
Anapl_17310 101795567 LOC101795567 CD48 antigen -6 1.72E-21
Anapl_05113 101803982 TMEM140 transmembrane protein 140 -5 3.36E-43
Anapl_17426 101804845  Anpl-DRA HLA class II histocompatibility antigen, DR alpha chain -5 2.65E-18
Anapl_05503 101802002 MORN3 MORN repeat containing 3 -4 2.26E-22
Anapl_03156 101797577 SCPEP1 serine carboxypeptidase 1 -4 3.09E-18
Anapl_18398 101793310 LOC101793310 transitional endoplasmic reticulum ATPase 10 2.15E-31
Anapl_18322 101803793 LOC101803793 E3 SUMO-protein ligase PIAS2 27 2.52E-19
Anapl_18875 101801464 LOC101801464 AN1-type zinc finger protein 5 46 4.54E-22
Anapl_18543 101798222 LOC101798222 transitional endoplasmic reticulum ATPase 51 1.13E-70
Anapl_18555 101791000 LOC101791000 heterogeneous nuclear ribonucleoprotein K 54 7.84E-88
Anapl_19040 101795174 LOC101795174 vasculin 63 1.81E-30
Anapl_18963 106020377 LOC106020377 60S ribosomal protein L37-like 173 1.46E-88
Anapl_18574 101790838 BTF3 transcription factor BTF3 255 5.86E-77
Fold change P-value
Upregulated 
Downregulated 
Feature ID Gene Symbol Gene DescriptionGeneID
Table 3. Significantly Differentially Expressed Genes of Infected Ducks vs. Control Ducks. (Additional information found 
in supplementary attached files) 
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Anapl_16761 101801882 LOC101801882 prolactin-releasing peptide receptor -1191 5.21E-137
Anapl_12933 101794704 LOC101794704 interferon alpha-inducible protein 27-like protein 2B -362 1.09E-79
Anapl_18401 101797569 LOC101797569 interferon-induced protein with tetratricopeptide repeats 5 -286 9.38E-307
Anapl_14386 101791352 RSAD2  viperin -150 3.64E-76
Anapl_13350 101793492  MX interferon-induced GTP-binding protein Mx-like -149 1.14E-37
Anapl_04893 101800938 LOC101800938 C-C motif chemokine 4-like -135 2.8E-44
Anapl_05957 101791974 PLAC8 placenta specific 8 -92 1.53E-65
Anapl_12350 101791431 IFITM1 interferon-induced transmembrane protein 1 -83 2.01E-15
Anapl_08494 101795904 IRF7 interferon regulatory factor 7 -77 3.13E-61
Anapl_18425 101800921 LOC101800921 uncharacterized LOC101800921 -62 5.44E-31
Anapl_02580 101793511  SAMD9 sterile alpha motif domain-containing protein 9 -56 1.63E-38
Anapl_13644 101804721 LYZ lysozyme -54 2.5E-130
Anapl_14385 101790338 CMPK2 cytidine/uridine monophosphate kinase 2 -50 1.88E-20
Anapl_13382 101798516 EIF2AK2 eukaryotic translation initiation factor 2 alpha kinase 2 -42 5.62E-24
Anapl_01685 101791385 LOC101791385 C-C motif chemokine 5-like -35 8.38E-83
Anapl_03170 101800860  SAMD9L sterile alpha motif domain-containing protein 9-like -30 3.32E-41
Anapl_01687 101791569 LOC101791569 C-C motif chemokine 4-like -28 2.73E-64
Anapl_19105 101790497  Anpl-U class I histocompatibility antigen -27 7.93E-22
Anapl_12150 101790417 DDX60 DExD/H-box helicase 60 -24 0.00867
Anapl_18444 101805361 PLVAP plasmalemma vesicle associated protein -22 1E-76
Anapl_16041 101797680 TAP1 transporter 1 -20 3.88E-18
Anapl_03154 101791574 TRIM25 tripartite motif containing 25 -18 5.65E-46
Anapl_09160 101796142 LOC101796142 interferon regulatory factor 4-like -18 1.11E-18
Anapl_06633 101798767 SELP  P-selectin -15 0.00000089
Anapl_18689 101797093 LOC101797093 uncharacterized LOC101797093 -15 1.44E-68
Anapl_01734 101799108 B2M beta-2-microglobulin -12 0
Anapl_03165 106014788 RNF135 ring finger protein 135 -11 9.6E-19
Anapl_06165 110351393 SRGN serglycin -11 1.14E-12
Anapl_02737 101791571 LOC101791571 uncharacterized LOC101791571 -11 9.21E-31
Anapl_12048 101803806 USP18 ubiquitin specific peptidase 18 -10 9.32E-62
Anapl_04499 101798590 LOC101798590  C-factor -10 0.000152
Anapl_17300 101799633 IRF1 interferon regulatory factor 1 -10 3.21E-50
Anapl_10830 101794086 LOC101794086  Avidin -10 0.000454
Anapl_00935 101798744  PARP14 poly [ADP-ribose] polymerase 14 -9 2.4E-11
Anapl_16039 101797091 TAP2 transporter 2 -8 8.69E-37
Anapl_10110 101789908 LOC101789908 poly [ADP-ribose] polymerase 14 -8 1.25E-40
Anapl_05044 101799009 TNNC1 troponin C1 -8 0.000000163
Anapl_12082 101801672 STC2 stanniocalcin 2 -8 2.08E-11
Anapl_09935 101790771 TLR3 toll like receptor 3 -7 0.00405
Anapl_18328 101794524 LOC101794524 desmin -7 1.72E-14
Anapl_12194 101792676  KRT15 keratin -6 0.0000016
Anapl_17040 101797128 LOC101797128 interferon-induced, double-stranded RNA-activated protein kinase-like -6 1.68E-31
Anapl_07454 101796809 LOC101796809 probable E3 ubiquitin-protein ligase HERC3 -6 8.13E-21
Anapl_18133 101789989  DES desmin -6 0.0000061
Anapl_18492 101804236 LOC101804236 interferon-induced  double-stranded RNA-activated protein kinase -5 9.25E-25
Anapl_10146 101797758 NMI N-myc and STAT interactor -5 4.4E-38
Anapl_06658 101804116  FMO5 dimethylaniline monooxygenase [N-oxide-forming] 5 -5 3.53E-09
Anapl_05113 101803982 TMEM140 transmembrane protein 140 -5 3.37E-23
Anapl_10109 101789724 PARP9 poly(ADP-ribose) polymerase family member 9 -5 0.00000591
Anapl_04378 101803758 C1QA complement C1q A chain -4 1.2E-35
Anapl_05119 101804899 MGP matrix Gla protein -4 0.000000162
Anapl_04377 101803105 C1QB complement C1q B chain -4 1.67E-27
Anapl_05503 101802002 MORN3 MORN repeat containing 3 -4 4.07E-08
Anapl_02710 101792273 ANXA2 annexin A2 -4 0.00000494
Anapl_09237 101802278 HEBP2 heme binding protein 2 4 1.48E-12
Anapl_07161 106017883 LOC106017883 uncharacterized LOC106017883 4 0.000104
Anapl_15348 101802855 CAMK1G calcium/calmodulin dependent protein kinase IG 4 0.000000211
Anapl_03384 101789775 NPPA natriuretic peptide A 4 0.00249
Anapl_00326 101795529 PLLP plasmolipin 4 2.87E-22
Anapl_07480 101792989 FA2H fatty acid 2-hydroxylase 4 0.00314
Anapl_02114 101797223 APOD apolipoprotein D 4 4.45E-08
Anapl_13900 101797552 GNG13 G protein subunit gamma 13 4 4.8E-13
Anapl_18398 101793310 LOC101793310 transitional endoplasmic reticulum ATPase 10 1.05E-10
Anapl_18322 101803793 LOC101803793 E3 SUMO-protein ligase PIAS2 16 0.0016
Anapl_18555 101791000 LOC101791000 heterogeneous nuclear ribonucleoprotein K 38 8.42E-36
Anapl_19040 101795174 LOC101795174 vasculin 41 8.93E-09
Anapl_18360 101793809 LOC101793809 ras GTPase-activating protein 1 50 0.00491
Anapl_18543 101798222 LOC101798222 transitional endoplasmic reticulum ATPase 52 5.78E-28
Anapl_18875 101801464 LOC101801464 AN1-type zinc finger protein 5 66 0.0000278
Anapl_18963 106020377 LOC106020377 60S ribosomal protein L37-like 201 6.68E-36
Anapl_18574 101790838 BTF3 transcription factor BTF3 258 1.07E-30
Downregulated 
Upregulated 
Feature ID Gene ID  Gene Symbol Gene Description Fold change P-value
Table 4. Significantly Differentially Expressed Genes of Clinical Sign Duck vs Control Ducks. (Additional 
information found in supplementary attached files) 
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3.3. Gene Ontology of PaBV-2 infected ducks 
 
To examine the correlation between differentially expressed genes and infection-induced 
biological processes, table 3 was uploaded onto the Database for Annotation, Visualization, and 
Integrated Discovery (DAVID). [94, 95]  A cutoff of P < 0.01 was set for Gene Ontology (GO) 
term enrichment. Results of the GO term enrichment indicated that two biological process 
groups were affected: immune system and cellular response to another organism (Figure 2). 
Immune system processes included immune response (15 genes), antigen processing and 
presentation (6 genes), response to chemical (12 genes), response to external stimulus (9 genes), 
immune effector process (5 genes), positive regulation of immune system process (5 genes), and 
regulation of immune system response (6 genes). Cellular response to another organism 
processes included multi-organism cellular process (6 genes), interspecies interaction between 
organisms (6 genes), response to other organism (6 genes), response to biotic stimulus (6 genes), 
and negative regulation of multi-organism process (3 genes). Individual genes of the 49 
differentially expressed genes associated with the GO term biological process are shown in 
figure 3.  
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Figure 2. Enriched Biological Process GO Terms of 49 Differentially Expressed Genes from Infected Ducks. Only enriched 
terms with a P < 0.01 and a fold change > |4| were used. Each section represents a GO term biological process, and the 
number of gene hits are next to each term. A gene can be included in more than one GO term biological process. 
Supplementary table 1 contains tables of genes associated with each depicted GO term. Genes for each labeled GO term are 
depicted in the table below. 
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Figure 3. Genes Associated with Each Depicted GO Term. Genes for each labeled GO term are depicted in the table below. 
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Table 5. Top 15 Selected Genes. Fold changes depicted are taken from the same values on Table 3.  
 
3.4. Major genes and pathways of PaBV-2 infection in duck brain 
 
Using the information from the comparisons between infected and control duck expression 
profiles and from GO enrichment, fifteen genes, based on their dysregulation and their function 
in both the cellular response to other organism and the immune system response, were selected 
for pathway analysis (Table 5).  
 
 
  
 
 
 
 
The genes were uploaded onto the Kyoto Encyclopedia of Genes and Genome (KEGG) 
pathway database. [96-98] Of the 20 pathways with hits for the duck in KEGG, two are 
pathways from viral infection and five pathways are part of the immune response. Viral 
infection pathways include the duck Influenza A pathway (8 genes), and the duck herpes 
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simplex infection pathway (8 genes). Pathways of the immune response included the toll-like 
receptor signaling pathway (3 genes), necroptosis pathway (2 genes), RIG-I-like receptor 
signaling pathway (2 genes), the cytosolic DNA-sensing pathway (2 genes), and the intestinal 
immune network for IgA production pathway (2 genes). Pathways and their correlating genes 
are depicted on table 6. 
 
 
Table 6. KEGG Pathway Analysis Results. Each pathway, number of gene hits, and genes in each pathway 
are depicted.  
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CHAPTER IV 
DISCUSSION  
 
4.1. Discussion on selected down-regulated genes related to the immune response 
 4.1.1. Pattern Recognition Receptor Signaling and Interferon Induction  
 
Tripartite motif containing 25 (TRIM25), toll-like receptor 3 (TLR3), Interferon 
regulatory factor 7 (IRF7) and interferon regulatory factor 1 (IRF1) genes are regulators of the 
innate immune response against viruses and are downregulated in PaBV-2 infection.  
 
 4.1.1.1. Tripartite Motif Containing 25 
 
Tripartite motif containing 25 (TRIM25) gene is necessary for activation of the RIG-I 
signaling pathway, a pattern recognition receptor (PRR) (Figure 4). Genetic mutations that 
disrupt TRIM25 function have downstream effects of decreasing signaling by RIG-I and IFN 
induction, and of antiviral activity. [123, 124] The non-structural protein 1 and nucleoproteins 
of Influenza A and SARS-CoV, respectively, bind TRIM25 to inhibit ubiquitination and 
activation of RIG-I in cell culture studies. [125, 126] Unlike these viruses, TRIM25 is 
inhibited by the binding with the subgenomic RNA of dengue virus. [127] Interestingly, of all 
the selected genes in our study, TRIM25 is unique in that the downstream effected RIG-1 gene 
is lacking in the chicken. This lack of RIG-I signaling pathway may be a reason why avian 
influenza is more virulent in chickens than in ducks and maybe a contributing factor in why 
mallard ducks are a reservoir species for avian influenza. [128] Additionally, borna disease 
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viruses (BDV) are able to evade the RIG-I signaling pathway as the 5’ end triphosphate group 
is replaced with a monophosphate group during BDV genomic replication, and this end 
triphosphate is not recognized by the RIG-I receptor. [129]  
 
4.1.1.2. Toll-like Receptor 3 
 
Toll-like Receptor 3 (TLR3) is an endosomal receptor that is shown to be expressed in 
the neurons of ducks. [130, 131] Viral RNA recognition by TLR3 activates the toll-like 
receptor pathway in avian species (Figure 4). [132] Toll-like receptor 3 is implicated in 
multiple neurotropic viruses as it is expressed on nerve cells and is able to induce the 
expression of type I interferons and proinflammatory chemoattractants. Viruses hijack TLR3 
and can either inhibit or enhance inflammation of the nervous system through TLR3 control. 
[131] West Nile virus is able to inhibit TLR3 signaling and subsequently type I interferon 
expression in cell culture. However in vivo, TLR3 signaling and the subsequent expression of 
type I interferons increases the permeability of the blood-brain barrier and facilitates West Nile 
virus entry into and infection of the brain. [133-136] In an infection by herpes simplex virus, 
the downregulation of TLR3 in mice brains increases the vulnerability of astrocytes to 
infection. [137] However, TLR3 can also be hijacked for viral replication. TLR3 is 
upregulated in response to infection by rabies virus in mice. [138] This is due to TLR3 being 
expressed on the inclusion bodies, called Negri Bodies, during rabies virus infection. 
However, when TLR3 is absent in knockout mice, Negri bodies fail to form and mice are 
rabies resistant. [139, 140] It should be noted that TLR3 is unique among toll-like receptors. 
TLR3 expression is upregulated by type I interferons (IFNα and IFNβ) in the central nervous 
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system. This is unlike most toll-like receptors that upregulate relative to viral load. 
Researchers postulate that this may aid in making cells more sensitive to neighboring infected 
cells in the central nervous system. [138]  
 
4.1.1.3.  Interferon Regulatory Factor 7 
 
Both the toll-like receptor pathway and the RIG-I receptor pathway activate interferon 
regulatory factors to induce the expression of type I interferons. Interferon regulatory factor 7 
(IRF7) is activated downstream of both the RIG-I and toll-like receptor signaling pathway 
(Figure 4). Interferon regulatory factor 7 forms a homodimer or heterodimer with IRF3 located 
in the cytosol. IRF7 is able to activate both IFNα and IFNβ, while IRF3 activates IFNβ, and 
both are constitutively expressed in cells. [141] Once activated by pattern recognition receptor 
signaling pathways, IRF7 and IRF3 migrate to the nucleus and bind to the type I interferon 
promoter regions to express IFNα and IFNβ. [140, 142]  However, IRF7 is the main regulator 
of type I IFN gene expression. In IRF7 knockout mice, severity of West Nile virus infection of 
mice was greater than that of IRF3 knockout mice. In addition to an increased severity, IRF7 
knockout mice had an expanded tissue tropism, increased viral load, and earlier entry into the 
central nervous system by West Nile virus than the IRF3 knockout mice. [141] This is not 
entirely unexpected as IRF7 induced interferons are able to induce the expression of over 300 
genes including signal transducer and activator of transcription 1 (STAT1), class I major 
histocompatibility complex (MHC I), and interferon-induced myxovirus resistance dynamin 
like GTPase (MX). [143, 144] Both rabies and borna disease virus are able to inhibit IRF7, and 
subsequently inhibit the induced antiviral state of a host cell, by different viral proteins (Figure 
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5). The phosphoprotein protein (P-protein) of rabies virus is able to block phosphorylation of 
IRF3 and IRF7 via the regulatory proteins proteins Traf family member associated-activator 
NF-κB (TANK) binding kinase-1 and inhibitor of nuclear factor kappa B kinase ϵ, 
respectively. This effectively inhibits expression of type I interferon genes. [140, 145] 
Interferon regulatory factor 7 is inhibited by the BDV nucleoprotein in oligodendroglia cells; 
however the mechanism of inhibition is unknown. IRF3 is inhibited by the BDV 
phosphoprotein because this protein is a competitive inhibitor of IRF3 to the TANK binging 
protein 1 binding site (Figure 5). [129, 136, 146-148]  
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Figure 4. Relationships between Top 15 Chosen Genes. Genes in maroon boxes are from the list of the top 15 
chosen genes. Grey ovals represent genes that are not part of the top 15 selected genes, but are involved in the 
top 15 gene downstream relationships. Arrows represent downstream relationships. 
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4.1.1.4. Interferon Regulatory Factor 1 
 
Interferon regulatory factor 1 (IRF1) is not induced by the PRR signaling pathways like 
IRF7. IRF1 is activated later in the viral replication cycle than IRF7. Interferon regulatory 
factor 1 is essential to inducing the antiviral effects of IFNγ which is released by natural killer 
cells (Figure 6). It is postulated that IRF1 induces a second wave of type I interferons through 
activation of the Jak/STAT pathway (Figure 4), which feedback into inducing genes through 
IRF7. This aids in maintaining an antiviral state in the host cell. [149, 150] Interferon 
regulatory factor 1 can be induced by IFNγ interferons released by natural killer cells. Upon 
activation, IRF1 binds to the IRF1 responsive element (IRF-E) which promotes expression of 
TAP1 and subsequently MHC I [151]. Interferon regulatory factor 1 knockout mice are 
deficient in natural killer cells and cytotoxic T-cells. [151, 152] Several important disease 
causing viruses are inhibited in cell culture by IRF1, possible through IRF1 effect on inducible 
transcripts that overlap with interferon induced transcripts (Figure 6). [153]  
 Interferon regulatory factor 1 has recently been isolated in mallard ducks, and its 
function is not dissimilar from human IRF1 as it is able to induce IFNβ. [154] In ducks, IRF1 
is an essential regulatory factor for the host antiviral response. When ducks were infected with 
avian influenza A, IRF1 was significantly activated, induced production of type I interferons 
and inhibited viral replication. [154]  Additionally while it is expressed in the spleen, liver, 
brain, and pancreas, upon stimulation with avian influenza virus, expression of IRF1 was 
found to be highest in the brain. [154] Vesicular stomatitis virus (VSV) infected mice cleared 
the infection, however IRF1 knockout mice succumbed to encephalitis caused by VSV 
infecting the central nervous system. Researchers postulate that IRF1 protects the host cell 
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later in the viral replication cycle, after the initial induction of type I interferons, and inhibits 
inflammation of the central nervous system in response to a VSV infection. [151, 155] 
 
4.1.2. Interferon Stimulated Genes  
 
The Interferon-induced myxovirus resistance dynamin like GTPase (MX), viperin 
(RSAD2), and the eukaryotic translation initiation factor 2 alpha kinase 2 (EIF2AK2) genes 
are constituently expressed in cells and are further induced by type I interferons. 
LOC101791569 is described as a C-C motif chemokine-4 like gene, which is expressed by 
innate immune cells (Figure 4). These genes produce chemokines induced by inflammation 
and an antiviral state in host cells. 
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Figure 5. Viral Interactions with the Top 15 Genes. Rabies virus phosphoprotein (P-protein) is able to inhibit 
phosphorylation of IRF7, via IKKi and TBK-1, and STAT1. The mammalian BV genome has a 
monophosphate 5’ end which is not recognized by the RIG-I receptor. Both mammalian and avian BV are able 
to inhibit RIG-I via the non-structural X protein in cell culture. The mammalian BV nucleoprotein  (N-
protein)protein can inhibit IRF7 function. The mammalian BV phosphoprotein (P-protein) can inhibit IRF3, 
which forms a dimer with IRF7. 
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4.1.2.1. Interferon-induced myxovirus resistance dynamin like GTPase 
 
The Interferon-induced myxovirus resistance dynamin like GTPase (MX) gene is 
known to protect against negative-stranded RNA by inhibiting viral replication or viral entry. 
By controlling vesicle trafficking in the cell, the MX protein is able to trap essential viral 
replicating proteins. [156, 157] The MX gene is further expressed by both type I and type II 
interferons (Figure 6). [158] The control of vesicle transport stimulates a broad antiviral 
response. MX restricts viral replication of viruses through blocking viral RNA from entering 
the nucleus, attacking viral nucleocapsids to prevent cytoplasmic mRNA replication, 
sequestering viral N proteins, and inhibiting viral integration into the host DNA. [158] 
Influenza virus replication is specifically blocked by MX inhibiting assembly of viral 
ribonucleoprotein complexes via the polymerase basic protein 2 (PB2) and nucleoprotein (NP) 
viral proteins necessary for viral replication in the host cell. [159] Both RIG-I and MX are 
upregulated in ducks when infected with a low pathogenic form of avian influenza virus. This 
is interesting as mallard ducks are a reservoir for avian influenza, a disease that is lethal to 
chickens and humans. [128, 160] The nucleoprotein is a main determinant of influenza A virus 
vulnerability to MX, but the nucleoproteins can vary amongst influenza A virus strains which 
causes variability in MX sensitivity. [161, 162] Increased sensitivity to MX may account for 
decreased virus success in mammals. [161, 162] Other than influenza A virus, MX is able to 
target rabies virus and inhibit replication similar to how MX is able to inhibit replication of 
VSV, two viruses in the same family. [163]  
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4.1.2.2. Viperin 
 
Viperin (RSAD2) is associated with the endoplasmic reticulum and protects the host 
cell against enveloped and RNA viruses. Viperin targets viruses to both inhibit initial viral 
replication, packaging, and release from the host cell. [157] Viperin in the duck is expressed in 
the brain, and is highly similar to other species including mammals. [164] Viperin expression 
is able to impair viral transmission in respiratory syncytial virus (RSV) infected cells by 
possibly inhibiting virus formation. [165]  
 
4.1.2.3. Eukaryotic Translation Initiation Factor 2 Alpha Kinase 2 
 
Eukaryotic translation initiation factor 2 alpha kinase 2 (EIF2AK2), also called PKR, 
functions to phosphorylate eIF2α which stops mRNA translation. It also has the ability to act 
as a cytosolic PRR and activate the RIG-I signaling pathway when it directly interacts with 
viral RNA (Figure 6). [166, 167] Other than RIG-I, EIF2AK2 interacts with multiple pattern 
recognition receptor pathways that regulate apoptosis, inflammation, and possibly the adaptive 
immune response. [156] While it is constitutively being expressed in cells, its expression is 
upregulated by type I and type II interferons (Figure 4). [156, 166, 167] Influenza A and B 
non-structural protein 1 inhibits EIF2AK2, however this same protein downregulated RIG-I 
signaling. [166] Ebola virus polymerase cofactor VP35 inhibits EIF2AK2 activation and 
inhibits IRF7 activation. [166] Both viruses inhibit EIF2AK3 expression by blocking proteins 
which signal the production of type I interferons. [166] Sendai virus C and human 
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parainfluenza virus type 1 produces proteins that limit RNA replication to avoid activation of 
antiviral EIF2AK2. [168]  
 The downregulation of these genes may be due to PaBV-2 inhibiting the function of 
STAT1. After STAT1 and STAT2 are activated by IFNα and IFNβ, the rabies virus 
phosphoprotein inhibits STAT1 and STAT2 function (Figure 5). Specifically, the 
phosphoprotein is able to bind to STAT1 so that the STAT complex cannot enter the nucleus, 
and the phosphoprotein can block the DNA promoters that STAT binds to activate. This 
blocks the host cell from carrying out an antiviral response by interferon stimulated genes, 
MX, EIF2AK2, and RSAD2. Interestingly, STAT1 is consistently upregulated in central 
nervous system infections of Japanese encephalitis virus, rabies virus, and sindbus virus. [140, 
144, 169]  
 
4.1.2.4. LOC101791569 (C-C Motif Chemokine-like) 
 
Chemokines, including LOC101791569, function to attract leukocyte or 
proinflammatory cells. [170] TLR3 activation mediates the inflammatory response as it 
regulates the production of cytokines and chemokines through the downstream proteins TNF 
receptor associated factor 6, inhibitor of nuclear factor kappa B kinase subunit epsilon, and 
nuclear factor kappa-light-chain-enhancer (Figure 4). Additionally, TLR3 mediates the 
infection of the brain by West Nile virus due to the increased expression of cytokines and 
chemokines increasing the permeability of the blood brain barrier. [133, 134] Expression of 
chemokines in rabies infection increases the permeability of the blood brain barrier to allow 
migration of immune cells including natural killer cells and T-cells. [171] In mammalian borna 
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disease virus (BDV) infected mice, there was significant upregulation of chemokines before 
leukocyte infiltration or neurological disease was seen in the central nervous system. However, 
the production of cytokines did not significantly occur from the abundantly infected astrocytes 
in the central nervous system of infected mice. Investigators theorize that the infection of BDV 
may be affecting the gene expression of chemokines. [172]  
 
4.1.3. Antigen Presentation Processing 
 
Transporter associated with antigen processing 1(TAP1), transporter associated with 
antigen processing 2 (TAP2), and cathepsin S (CTSS) are essential genes in the antigen 
presentation pathway. These genes control the expression of Anpl-U (MHCI), Anpl-DRA 
(MHCII), LOC101789604 (MHCII), and beta-2-microglobulin (B2M)(Figure 4). Without both 
TAPs, no MHC I would reach the cell surface, and CTSS is necessary to release MHC II, 
including B2M, proteins to the cell surface. Additionally, expression of these genes begins to 
overlap with previously mentioned downregulated genes of the immune system response.  
 
4.1.3.1. Transporter associated with antigen processing 1 and 2 
 
Expressed on the endoplasmic reticulum, TAP1 and TAP2 are two proteins of the TAP 
heterodimer that function to transport degraded peptides in the antigen presentation process. 
MHC I (Anpl-U) complex is bound to TAP which loads digested antigen peptides onto it. 
Only then can the MHC I be displayed on the cell membrane. [151, 173] Transporter 
associated with antigen processing genes are in close proximity to MHC I, MHC II, B2M 
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genes on the duck genome, and IRF1 is able to induce expression of the TAP gene (Figure 6). 
[151, 174] Additionally, upregulation of TAP1 gene expression is associated to an 
upregulation in the expression of MHC I in cell culture. This mechanism was used to avoid 
cell death via natural killer cells during a hepatitis C virus infection. [175] 
 
4.1.3.2. Cathepsin S 
 
Cathepsin S (CTSS) performs proteolysis on the bond between CD74 and MHC II, and 
frees MHC II (Anpl-DRA, LOC101789604, and B2M) to migrate to the cell surface. [176] 
Cathepsin S gene expression does not change when chemokines and cytokines, including 
IFNγ, TNFα, are released, indicating that CTSS expression is independent of interferon 
expression. Additonally, cathepsin S is not expressed in astrocytes but is expressed in the 
microglia of the central nervous system in mice. [177] The antigen presentation process in the 
central nervous system is significantly hindered when CTSS is impaired. Additionally, 
expression of CD74 is able to regulate the expression of CTSS, but chemokines and cytokines 
do not in the central nervous system. [177] Finally, cathepsin S is upregulated across 3 
different neurotropic viral infections in mice including rabies virus, Japanese encephalitis, and 
sindbis virus. [169]  
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Figure 6. Cross Interactions with the Top 15 Genes. EIF2AK2 recognizes viral genomes and in turn can 
activate the RIG-I signaling pathway. Natural killer cells and CD8+ cytotoxic T-cells release IFNγ which is 
able to activate both IRF1 and IRF7. IRF1 can in turn activate interferon stimulated genes and TAP1. The 
induction of type I interferons interact with IRF7 through positive feedback. 
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CHAPTER V 
CONCLUSION 
 
In our study, we identified differentially expressed genes in ducks infected with PaBV-2. 
Of these differentially expressed genes, a majority of the genes downregulated at least by 4-
fold change from the infected ducks were related to immunology and viral recognition. 
Unexpectedly, we were able to obtain differentially expressed genes from an infected duck that 
also exhibited severe ataxia. Clinical signs in ducks due to PaBV-2 infection have not been 
previously observed in North America. This is the first observation of PDD-like clinical signs 
with neurological involvement in avian bornavirus infected waterfowl.  
While significant, this study is not without its limitations. First, the duck genome is not 
fully annotated and functions of certain genes are still to be fully elucidated. Secondly, while 
this study used PaBV-2 infected mallard ducks, PaBV-2 is not known to naturally infect 
mallard ducks. Noting these limitations, this study is relevant as ducks can be experimentally 
infected with PaBV-2, PDD is an avian disease, and most importantly, there is not a standard 
reference genome in other PaBV bird model such as conures or cockatiels. With this study, 
precedence has been set for the use of RNA-Seq in the research of PaBV infection. This study 
showed immunologically relevant genes are differentially expressed in ducks infected with 
PaBV-2 and this study is the first of its kind to use RNA-Seq in the study of PaBV.  
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APPENDIX A                                                                                                                                                                                                                                               
 Figure.A1: Original RNA isolation protocol and troubleshooting (Macheney-Nagel Inc.) 
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(Macherey-Nagel Inc.) 
 64 
 
Table A1.  List of tissues taken for PCR and histopathology  
PCR  
samples 
Histopathology 
Samples 
Cerebellum Lung 
Hindbrain Heart 
Forebrain Liver 
Midbrain Small intestine 
Spinal cord Proventriculus 
Eye Adrenal gland 
Optic nerve Sciatic nerve 
Aqueous 
humor Brachial plexus 
Intestine Optic nerve 
Adrenal gland Cerebrum 
Kidney Cerebellum 
Proventriculus Bursa of Fabricious 
Ventriculus Cloaca 
Crop Uterus 
 Muscle 
 Ventriculus 
 Spleen 
 Pancreas 
 
Table A2. Mallard duck genome contigs and annotations 
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 Table A3. Normal Reads Checks
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 Figure A2. CLC Importation parameters: RNA (Qiagen Inc.)
 
 Figure A3. CLC tool:  RNA-Seq Analysis (Qiagen Inc.) 
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 Figure A4. CLC tool:  Annotation with GFF file (Qiagen Inc.)
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 Figure A5. CLC tool: Set Up Experiment (Qiagen Inc.) 
appendix
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 Figure A6. CLC tool:  Empirical Analysis by DGE (Qiagen Inc.) 
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APPENDIX B  
 
 Table B1. Cloacal swab PCR and Mass of Ducks Results  
 
 Table B2. Detailed RT-PCR and Western Blot Results  
 
 
C1 C2 C3 I1 I2 CS
Western Blot Results
Serum - - - + - +
PCR Results
Cerebellum - - - + + +
Hindbrain - - - + + +
Forebrain +
Midbrain +
Spinal cord +
Eye +
Optic Nerve +
Aqueous Humor +
Intestine +
Adrenal Gland +
Kidney +
Proventriculus +
Ventriculus +
Crop +
Bursa
Controls Infected
PCR and Western Blot Results 
